Viatris Innovation
Part of Viatris
CompanyUnited States
Viatris Innovation develops one asset, in phase 3 (selatogrel in acute myocardial infarction). Mostly small molecule acting on P2RY12; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 6
- Trials
- 0
- Signals
Pipeline
1P2Y12 platelet receptor antagonist inhibiting platelet aggregation
Phase 3, Small molecule, P2RY12, acute myocardial infarction, chronic coronary syndrome (Phase 1)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials6
- Signals1
- Similar companies6